Evaluation of Heterozygous Deletion of TP53 Gene in Pleural Fluid Samples: A Case Series of 11 Patients


DIRICAN N., BAGCI O., UZ E. , ÖZTÜRK Ö. , BİRCAN H. A. , Dirican A.

JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, vol.7, pp.165-167, 2016 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 7
  • Publication Date: 2016
  • Doi Number: 10.4328/jcam.4551
  • Title of Journal : JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE
  • Page Numbers: pp.165-167

Abstract

We described heterozygous deletion of tumor protein 53 (TP53) gene in 11 patients including 2 patients with non- malignant diseases (pneumonia) and 9 patients with malignant diseases [including small cell lung cancer (n = 3), non-small cell lung carcinoma (n = 4), non-Hodgkin's lymphoma (n= 1), and gastric carcinoma (n= 1)]. Chromosomal aberrant status was analyzed by fluorescence in situ hybridization with centromere specific and 17p13.1 locus specific probes. In 3 of 9 cancer patients we did not find malignant pleural effusion with histological examination and/or closed pleural biopsy. Heterozygous deletion of TP53 gene was found to be significantly higher in patients with malignant disease when compared to the patients with benign pleural fluid. As a result, we suggest that heterozygous deletion of TP53 may have indicator value for malignancy; however further studies are warranted to confirm this suggestion in large patient cohorts.